WO2001045642A3 - Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease - Google Patents

Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease Download PDF

Info

Publication number
WO2001045642A3
WO2001045642A3 PCT/US2000/042821 US0042821W WO0145642A3 WO 2001045642 A3 WO2001045642 A3 WO 2001045642A3 US 0042821 W US0042821 W US 0042821W WO 0145642 A3 WO0145642 A3 WO 0145642A3
Authority
WO
WIPO (PCT)
Prior art keywords
systemic
disease
levovirin
ribavirin
type
Prior art date
Application number
PCT/US2000/042821
Other languages
French (fr)
Other versions
WO2001045642A2 (en
Inventor
Fuesun Zeytinoglu
Original Assignee
Icn Pharmaceuticals
Fuesun Zeytinoglu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals, Fuesun Zeytinoglu filed Critical Icn Pharmaceuticals
Priority to AU50766/01A priority Critical patent/AU5076601A/en
Publication of WO2001045642A2 publication Critical patent/WO2001045642A2/en
Publication of WO2001045642A3 publication Critical patent/WO2001045642A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Abstract

A method of treating a systemic viral disease in a patient has a first step in which the disease is correlated with an increase in Type 1 cytokine activity and a decrease in Type 2 activity. In a further step, a systemic dosage of a drug is identified that is effective to increase the Type 1 activity and decrease the type 2 activity, wherein the drug is Ribavirin or Levovirin™ and in a still further step, the dosage of the drug is administered to the patient via pulmonary delivery. A further method of treating a viral disease has a first step in which the disease is correlated with an infection of dendritic cells, and the dendritic cells are targeted by administering Ribavirin or Levovirin™ via a pulmonary aerosol.
PCT/US2000/042821 1999-12-13 2000-12-13 Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease WO2001045642A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50766/01A AU5076601A (en) 1999-12-13 2000-12-13 Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45966899A 1999-12-13 1999-12-13
US09/459,668 1999-12-13

Publications (2)

Publication Number Publication Date
WO2001045642A2 WO2001045642A2 (en) 2001-06-28
WO2001045642A3 true WO2001045642A3 (en) 2001-12-13

Family

ID=23825713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042821 WO2001045642A2 (en) 1999-12-13 2000-12-13 Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease

Country Status (2)

Country Link
AU (1) AU5076601A (en)
WO (1) WO2001045642A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2011150441A1 (en) * 2010-06-03 2011-12-08 Wholesome Biopharm Pty Ltd Medical aerosol formulation comprising ribavirin
CN106061984A (en) 2014-02-13 2016-10-26 配体药物公司 Prodrug compounds and their uses
CN106687118A (en) 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABSTRACT, J. AM. MED. ASSOC., vol. 249, no. 19, 1983, pages 2666 - 2670 *
ABSTRACT, J. GENERAL VIROLOGY, vol. 79, October 1998 (1998-10-01), pages 2381 - 2391 *
DATABASE CAPLUS [online] COLUMBUS, OHIO, USA; HALL ET AL.: "Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults", XP002943621, accession no. CAS Database accession no. AN1983:482077 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); HULTGREN ET AL.: "The antiviral compound ribavirin modulates the T helper(Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses", XP002943622, accession no. STN Database accession no. 1998451323 *

Also Published As

Publication number Publication date
WO2001045642A2 (en) 2001-06-28
AU5076601A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
JP2001515712A5 (en)
JPH10506640A (en) Use of ribavirin and interferon alpha for the treatment of hepatitis C
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
EP0911033A3 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
KR20050055053A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
AU1079701A (en) Oral transmucosal drug dosage using solid solution
SE9703191L (en) Drugs for improving muscle function duration or treatment of muscle disorders or disease
WO2004041245B1 (en) Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
SG146638A1 (en) Pharmaceutical delivery system
JP2004537500A5 (en)
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
AR022116A1 (en) COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
JP2002530353A5 (en)
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
JP2001288110A5 (en)
JP2002529515A5 (en)
James Ribavirin approved for hepatitis C combination treatment
US5698232A (en) Pharmaceutical composition for treatment of sudden deafness
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP